ClinicalTrials.gg
CompletedNCT04945460CADENCEUpdated Sep 23, 2026Results posted

A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

A Phase 2 interventional study of Sotatercept 0.3 mg/kg and Placebo in Hypertension, Pulmonary, sponsored by Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA. Completed at 119 sites in 12 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 397 studies in Hypertension, Pulmonary with a site in United States — 73 open to participants now, 87 under way, 9 of them phase 3. Hypertension, Pulmonary · United States.

Enrollment
60th of 286
165 · median 30
Started
2021
with 11 others
Phase 2
93 of 397
13 open now
Registered
311th of 397
by date

Among the 397 studies in Hypertension, Pulmonary with a site in United States, this one is the 60th largest by enrollment of the 286 interventional ones that give a count, is one of 12 that started in 2021, is one of 93 in phase 2, and was the 311th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

73 of the 397 studies in Hypertension, Pulmonary with a site in United States are open now. Recruiting first, the newest first:

68 more — sign in →

All 73 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 397 studies in Hypertension, Pulmonary with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of sotatercept versus placebo in adults with Cpc-PH due to HFpEF.

The objective of this study is to evaluate the efficacy, safety and tolerability of sotatercept versus placebo in adults with Cpc-PH due to HFpEF. Efficacy is measured by change from baseline in pulmonary vascular resistance (PVR, primary endpoint) and 6-minute walk distance (6MWD, key secondary endpoint).

Read the detailed description

Participants enrolled in the study will have a diagnosis of Cpc-PH due to HFpEF with New York Heart Association (NYHA) functional class (FC) II or III. Participants will be randomly assigned in a 1:1:1 ratio to 1 of the 3 treatment groups (placebo, 0.3mg/kg sotatercept and 0.7mg/kg sotatercept) during the placebo-controlled Treatment Period. In the extension phase, sotatercept-treated participants will continue on their current dose. Placebo participants will be re-randomized in a 1:1 ratio to one of the two sotatercept treatment groups utilized in the placebo-controlled Treatment Period. Each participant will be enrolled in the study for up to 114 weeks, including a 28-day Screening Period, a 24-week, double-blind, placebo-controlled Treatment Period, an 18-month Extension Period, and an 8-week Follow-up Period.

As of protocol amendment 6, the 18-month Extension Period is being removed. Participants who have completed at least the 24-week placebo controlled treatment period and the end of study visit, and who have not discontinued study treatment early, may be eligible to participate in an extension study.

03

Conditions studied

  • Hypertension, Pulmonary

Keywords

  • Pulmonary, hypertension, Cpc PH, HFpEF, sotatercept
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet the following criteria to be enrolled in this proof-of-concept study:

  1. Age 18 to 85 years
  2. Clinical diagnosis of HFpEF:

    • ≥50%, with no history of LVEF below 45% in more than two consecutive measurements under stable conditions
  3. Demonstrated Cpc-PH by all of the following:

    • Baseline RHC performed within 28 days of randomization documenting a minimum PVR of ≥320 dyn•sec/cm5 (4 wood units)
    • Mean pulmonary arterial pressure (mPAP) of >20 mmHg
    • Pulmonary capillary wedge pressure (PCWP) >15 mmHg but \< 30 mmHg
  4. FC of II or III
  5. Six-minute Walk Distance ≥100 m repeated twice during Screening and both values within 15% of each other, calculated from the highest value
  6. Chronic medication for HF or for any underlying condition, administered at a stable (per investigator) dose for ≥30 days prior to Visit 1. Diuretics and/or anticoagulants are excepted from this rule but should not be newly started or stopped within 30 days of Visit 1, and a prescribed dose change should not occur within 7 days of Visit 1. Anticoagulation may be suspended for RHC if necessary
  7. Women of must:

    • Have 2 negative urine or serum pregnancy tests as verified by the investigator during the Screening Period; must agree to ongoing pregnancy testing during the course of the study and until 8 weeks after the last dose of the study drug
    • If sexually active with a male partner: use highly effective without interruption for at least 28 days prior to starting the product AND agree to use the same highly effective contraception in combination with a barrier method during the study (including dose interruptions), and for 16 weeks (112 days) after discontinuation of study treatment
    • Refrain from breastfeeding a child or donating blood, eggs, or ovum for the duration of the study and for at least 16 weeks (112 days) after the last dose of study drug
  8. Male participants must:

    • Agree to use a condom, defined as a male latex condom or non latex condom NOT made out of natural (animal) membrane (e.g., polyurethane), during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions, and for at least 16 weeks (112 days) following investigational product discontinuation, even if he has undergone a successful vasectomy
    • Refrain from donating blood or sperm for the duration of the study and for 16 weeks (112 days) after the last dose of study drug
  9. Ability to adhere to the study visit schedule and understand and comply with all protocol requirements
  10. Agreement to not participate in any other trials of investigational drugs/devices while enrolled in the A011-16 study
  11. Ability to understand and provide documented consent for participation

Exclusion criteria

Exclusion Criteria:

Participants will be excluded from the study if any of the following criteria are met:

  1. A diagnosis of PH in WHO Group 1, WHO Group 3, WHO Group 4, or WHO Group 5
  2. and active lung disease:

    • with post-bronchodilator (FEV1) \<60% predicted
    • Restrictive lung disease with total lung capacity \<70% predicted
    • More than mild interstitial lung disease (ILD), with FVC\<70% or FEV1\<60% predicted (still appropriate if absence of more than mild ILD, fibrosis, or COPD on computed tomography [CT] imaging)
  3. Cardiovascular co-morbidities, which include any of the following:

    • History of more than mild mitral or aortic stenosis
    • Ongoing more than mild mitral or aortic regurgitation
    • More than one valve replacement or repair (mechanical or biomechanical) or anticipation of any valve replacement or repair
    • Severe tricuspid regurgitation due to primary valvular disease
    • Occurrence of myocardial infarction, acute coronary syndrome, coronary artery bypass graft or percutaneous coronary intervention within 180 days of Visit 1
    • History of serious life-threatening or hemodynamically significant arrhythmia
    • History of or anticipated heart transplant or ventricular assist device implantation
    • History of implantable cardioverter defibrillator placement or anticipated implantation of pacemaker, pacemaker implantation within 30 days of Screening
    • Anticipated implantation of pacemaker, pacemaker implantation within 30 days of Screening or history of implantable cardioverter defibrillator placement
    • Occurrence of myocardial infarction within 180 days of Visit 1
    • History of known pericardial constriction, hypertrophic cardiomyopathy, sarcoidosis, or amyloid cardiomyopathy
    • Uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure >160 mmHg or sitting diastolic blood pressure >110 mmHg during Screening after a period of rest
    • Systemic hypotension as evidenced by sitting systolic blood pressure \<90 mmHg or sitting diastolic blood pressure \<50 mmHg during Screening
    • Resting heart rate of \<45 bpm or >115 bpm
    • Stroke within 90 days of Visit 1
    • Acutely decompensated HF that required hospitalization within 30 days of Visit 1
    • during Screening Period with Fridericia's interval (QTcF) >470 msec for males or >480 msec for females, or >500 msec if a ventricular conduction defect (right bundle branch block; left bundle branch block; or interventricular conduction delay) is present
    • Personal or family history of Brugada syndrome, sudden cardiac arrest or unexplained sudden cardiac death or arrest
    • Personal or family history of long QT syndrome unless the participant's ECG shows a normal QTc
    • Arrhythmogenic right ventricular dysplasia (ARVD) unless the participant has a recent cardiac MRI that shows no evidence of this diagnosis
  4. Hospitalization for any worsening of medical conditions or any significant surgery per investigator within 30 days of Visit 1
  5. Received any approved PAH-specific therapies (i.e., endothelin receptor antagonists, prostacyclin analogs, phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators) within 30 days of Visit 1.The use of an oral phosphodiesterase type 5 inhibitor, if only indicated for erectile dysfunction, is permitted, if not administered within 48 hours of a study visit or procedure
  6. Received intravenous inotropes (e.g., dobutamine, dopamine, norepinephrine, vasopressin, or levosimendan) within 30 days of Visit 1
  7. Received erythropoietin within 6 months of Visit 1
  8. Known history of chronic liver disease, including untreated and/or (with evidence of recent infection and/or active virus replication), with severe hepatic impairment and/or cirrhosis (e.g., hepatic encephalopathy)
  9. Prior exposure to sotatercept or luspatercept
  10. Currently enrolled in or have completed any other product study within 30 days for small molecule drugs or within 5 half-lives for investigational biologics prior to the date of documented consent
  11. Initiation of an exercise program for cardiopulmonary rehabilitation within 90 days of Visit 1 or planned initiation during the study (participants who are stable in the maintenance phase of a program and who will continue for the duration of the study are eligible)
  12. Any of the following clinical laboratory values prior to Visit 1 as specified:

    • (Hgb) above the gender-specific (ULN) per local laboratory test within 28 days of Visit 1or \<10 g/dL per local laboratory within 28 days of Visit 1
    • Serum or aspartate aminotransferase levels >3× ULN or total >3× ULN within 28 days of Visit 1
    • Estimated \<30 ml/min/1.73 m2 (4-variable Modification of Diet in Renal Disease equation) within 28 days of Visit 1 or required renal replacement therapy within 90 days of Visit 1
    • (HbA1c) >10% within 28 days of Visit 1
    • count \< 75,000/mm3 within 28 days of Visit 1
  13. History of severe allergic or anaphylactic reaction or to recombinant proteins or in the investigational product
  14. Major surgery within 60 days of Visit 1. Participants must have completely recovered from any previous surgery prior to Visit 1
  15. Prior organ transplantation (e.g., heart, lung, liver, kidney), bone marrow transplantation, or of \< 12 months
  16. Pregnancy or breastfeeding in females
  17. Active , with the exception of fully excised or treated basal cell carcinoma, cervical carcinoma in situ, or ≤ 2 squamous cell carcinomas of the skin
  18. History of clinically significant (as determined by the investigator) endocrine, hematologic, hepatic, (auto)immune, infectious (requiring chronic antibiotics), metabolic, urologic, pulmonary, neurologic, neuromuscular, dermatologic, psychiatric, renal, and/or another disease that may limit participation in the study
  19. ≥50 kg/m2
  20. More than mild obstructive sleep apnea (treated or untreated)
  21. Any non-cardiopulmonary condition or acute/chronic impairment(s) (other than dyspnea) that limits the ability to perform 6-minute walk test (6MWT)
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
165 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Delivered subcutaneously (SC) every 3 weeks (Q3W) for 24 weeks in the placebo-controlled treatment period.

    Drug: Placebo

  • Experimental
    Sotatercept 0.3 mg/kg

    Participants will receive sotatercept SC at a dose level of 0.3 mg/kg Q3W for 24 weeks in the placebo-controlled treatment period.

    Drug: Sotatercept 0.3 mg/kg

  • Experimental
    Sotatercept 0.3 mg/kg, escalating to 0.7 mg.kg

    Sotatercept SC at a starting dose level of 0.3 mg/kg for 3 dosing visits (Q3W), then escalating to 0.7 mg/kg SC on the fourth dosing visit and Q3W for the remainder of the 24-week treatment Period.

    Drug: Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg

Interventions

  • DrugSotatercept 0.3 mg/kg

    Drug page: Sotatercept

    Administered by subcutaneous injection. Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.

    Also known as: ACE-011

  • DrugPlacebo

    Administered by subcutaneous injection

  • DrugSotatercept 0.3 mg/kg escalating to 0.7 mg/kg

    Drug page: Sotatercept

    Administered by subcutaneous injection. Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.

    Also known as: ACE-011

06

What researchers measure

Primary outcomes

  1. Base Study: Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24

    PVR, a hemodynamic variable of pulmonary circulation, was measured by right heart catheterization (RHC). Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Base Study: Change From Baseline in the 6-Minute Walk Distance (6MWD) at Week 24

    The 6MWD was performed to assess functional capacity. The 6MWD was assessed using the 6-minute walk test (6MWT) to measure the distance covered over a time period of 6 minutes. An increase in the distance walked during the 6MWT indicated improvement in functional exercise capacity. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.

    Time frame: Baseline and Week 24

  2. Base Study: Time to First Clinical Worsening Event (TTCW) at Weeks 24

    Clinical Worsening events were defined as the number of weeks from first dose date to any of the following: * Hospitalization due to a cardiopulmonary indication (a non-elective hospitalization lasting at least 24 hours in duration caused by clinical conditions directly related to Pulmonary Hypertension and/or Heart Failure) * Administration of intravenous diuretics or subcutaneous (SC) furosemide * Death (all causes) * Decrease in 6 minute walk distance (6MWD) by ≥15% from baseline confirmed by 2 tests at least 4hours, but no more than 1 week apart.

    Time frame: 24 Weeks

  3. Base Study: Change From Baseline in Mean Pulmonary Arterial Pressure (mPAP) at Week 24

    mPAP was calculated from systolic and diastolic pulmonary artery pressure measured by right heart catheterization. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.

    Time frame: Baseline and Week 24

  4. Base Study: Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP) at Week 24

    PCWP is an indirect estimate of left atrial pressure measured in right heart catheterization. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.

    Time frame: Baseline and Week 24

  5. Base Study: Change From Baseline in Tricuspid Annular Plane Systolic Excursion (TAPSE) at Week 24

    TAPSE is an echocardiographic measurement of tricuspid valve annulus movement, as an indicator of right heart function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.

    Time frame: Baseline and Week 24

  6. Base Study: Change From Baseline in Right Ventricular Fractional Area Change (RVFAC) at Week 24

    RVFAC is an echocardiographic measurement of percent change between right ventricular area during diastole and systole, as an indicator of right heart function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.

    Time frame: Baseline and Week 24

  7. Base Study: Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Week 24

    LVEF is an echocardiographic measurement of percent change between left ventricular volume during diastole and systole, as an indicator of left heart function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.

    Time frame: Baseline and Week 24

  8. Base Study: Change From Baseline in Isovolumic Relaxation Time (IVRT) at Week 24

    IVRT is an echocardiographic measurement of the interval between closure of the aortic valve, to onset of filling by opening of the mitral valve. It was used as an indicator of diastolic dysfunction. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.

    Time frame: Baseline and Week 24

  9. Base Study: Change From Baseline in Ratio of Mitral Inflow Velocity E to Mitral Annular Velocity'(e') (E/e' Ratio) at Week 24

    E/e' is a ratio of mitral inflow velocity E to mitral annular velocity (e') as measured by electrocardiography as an indicator of diastolic function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.

    Time frame: Baseline and Week 24

  10. Base Study: Change From Baseline in the Ratio of the Peak Velocity Flow of the E Wave in Early Diastole to Peak Velocity Flow of the A Wave in Late Diastole (E/A Ratio) at Week 24

    E/A is a ratio of the peak velocity flow of the E wave in the early diastole to peak velocity flow of the A wave in late diastole measured by echocardiography as an indicator of diastolic function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.

    Time frame: Baseline and Week 24

  11. Base Study: Change From Baseline in N-terminal Pro-hormone Brain Natriuretic Peptide (NT-proBNP) at Week 24

    NT-proBNP is a circulating biomarker that reflects myocardial stretch. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.

    Time frame: Baseline and Week 24

  12. Base Study: Change From Baseline in New York Heart Association Functional Class (NYHA FC) at Week 24

    NYHA FC classified the extent of heart failure (HF). Participant HF symptoms were graded using the NYHA FC system. NYHA FC for HF ranges from Class I (no limitation of physical activity, or ordinary physical activity does not cause undue fatigue, palpitation, dyspnea \[shortness of breath\]), Class II (slight limitation of physical activity, comfortable at rest, or ordinary physical activity results in fatigue, palpitation, dyspnea \[shortness of breath\]), Class III (marked limitation of physical activity, comfortable at rest, or less than ordinary activity causes fatigue, palpitation, or dyspnea) and Class IV (unable to carry on any physical activity without discomfort, symptoms of HF at rest or if any physical activity is undertaken, discomfort increases). Participants were classified as "Improved or Maintained" or "Not Improved nor Not Maintained". Improved or Maintained = reduction in NYHA FC or no change in NYHA FC; Not Improved nor Not Maintained = increase in NYHA FC.

    Time frame: Baseline and Week 24

  13. Base Study: Change From Baseline in Myocardial Contraction Fraction (MCF) at Week 24

    MCF is an echocardiographic measurement that determined the ratio of left ventricular stroke volume to myocardial volume and was an indicator of left ventricular systolic function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.

    Time frame: Baseline and Week 24

  14. Base Study: Number of Participants With One or More Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE was reported.

    Time frame: Up to approximately 6 months

  15. Base Study: Number of Participants Who Discontinued Study Treatment Due to an AE

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE was reported.

    Time frame: Up to approximately 6 months

07

Results

Posted Sep 23, 2026

Participant flow

Base Study
Participant flow — Base Study
MilestonePlacebo-Controlled Treatment Period: Sotatercept 0.3 mg/kgPlacebo-Controlled Treatment Period: Sotatercept 0.7 mg/kgPlacebo-Controlled Treatment Period: PlaceboExtension Period: Sotatercept 0.3 mg/kgExtension Period: Sotatercept 0.7 mg/kgExtension Period: Placebo → Sotatercept 0.3 mg/kgExtension Period: Placebo → Sotatercept 0.7 mg/kg
Started5456550000
Completed5249490000
Not completed2760000
Withdrew: Adverse event0100000
Withdrew: Death0020000
Withdrew: Withdrawal by subject1320000
Withdrew: Randomized in error without receiving study treatment0100000
Withdrew: Change in health status0010000
Withdrew: Unwillingness or inability to comply with protocol1210000
Extension Study
Participant flow — Extension Study
MilestonePlacebo-Controlled Treatment Period: Sotatercept 0.3 mg/kgPlacebo-Controlled Treatment Period: Sotatercept 0.7 mg/kgPlacebo-Controlled Treatment Period: PlaceboExtension Period: Sotatercept 0.3 mg/kgExtension Period: Sotatercept 0.7 mg/kgExtension Period: Placebo → Sotatercept 0.3 mg/kgExtension Period: Placebo → Sotatercept 0.7 mg/kg
Started00052472223
Completed00027201210
Not completed00025271013
Withdrew: Adverse event0002100
Withdrew: Death0001321
Withdrew: Withdrawal by subject0003702
Withdrew: Participants ongoing000161679
Withdrew: Elevation of hemoglobin values0000001
Withdrew: Worsening hemodynamics0001000
Withdrew: Participant request, did not withdraw consent0001000
Withdrew: Unwillingness or inability to comply with protocol0001010

Outcome measures

PrimaryBase Study: Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24

PVR, a hemodynamic variable of pulmonary circulation, was measured by right heart catheterization (RHC). Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.

Time frame:
Baseline and Week 24
Reported as:
Median · dynes*sec/cm5
Base Study: Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24
dynes*sec/cm5Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kgPlacebo-Controlled Treatment Period: Sotatercept 0.7 mg/kgPlacebo-Controlled Treatment Period: Placebo
Base Study: Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24-53.7 (-67.2 to -47.7)-26.0 (-36.4 to -3.5)21.1 (16.7 to 24.8)
Statistical analysis
  • Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg vs Placebo-Controlled Treatment Period: Placebo · Wilcoxon (Mann-Whitney) · p = 0.004 (One-sided p-values are provided using the aligned rank stratified Wilcoxon test stratified by the randomization stratification factor.) · Hodges-lehmann location shift: -81.51 · 95% CI -144.42 to -18.61
  • Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg vs Placebo-Controlled Treatment Period: Placebo · Wilcoxon (Mann-Whitney) · p = 0.024 (One-sided p-values are provided using the aligned rank stratified Wilcoxon test stratified by the randomization stratification factor.) · Hodges-lehmann location shift: -59.80 · 95% CI -121.86 to 2.27
SecondaryBase Study: Change From Baseline in the 6-Minute Walk Distance (6MWD) at Week 24

The 6MWD was performed to assess functional capacity. The 6MWD was assessed using the 6-minute walk test (6MWT) to measure the distance covered over a time period of 6 minutes. An increase in the distance walked during the 6MWT indicated improvement in functional exercise capacity. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.

Time frame:
Baseline and Week 24
Reported as:
Median · Meters
Base Study: Change From Baseline in the 6-Minute Walk Distance (6MWD) at Week 24
MetersPlacebo-Controlled Treatment Period: Sotatercept 0.3 mg/kgPlacebo-Controlled Treatment Period: Sotatercept 0.7 mg/kgPlacebo-Controlled Treatment Period: Placebo
Base Study: Change From Baseline in the 6-Minute Walk Distance (6MWD) at Week 2414.2 (10.1 to 16.3)-6.4 (-10.1 to -2.0)-0.3 (-3.5 to 1.5)
Statistical analysis
  • Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg vs Placebo-Controlled Treatment Period: Placebo · Wilcoxon (Mann-Whitney) · p = 0.017 (One-sided p-values are provided using the aligned rank stratified Wilcoxon test stratified by the randomization stratification factor.) · Hodges-lehmann location shift: 20.29 · 95% CI 1.48 to 39.11
  • Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg vs Placebo-Controlled Treatment Period: Placebo · Wilcoxon (Mann-Whitney) · p = 0.295 (One-sided p-values are provided using the aligned rank stratified Wilcoxon test stratified by the randomization stratification factor.) · Hodges-lehmann location shift: 5.80 · 95% CI -17.33 to 28.92
SecondaryBase Study: Time to First Clinical Worsening Event (TTCW) at Weeks 24

Clinical Worsening events were defined as the number of weeks from first dose date to any of the following: * Hospitalization due to a cardiopulmonary indication (a non-elective hospitalization lasting at least 24 hours in duration caused by clinical conditions directly related to Pulmonary Hypertension and/or Heart Failure) * Administration of intravenous diuretics or subcutaneous (SC) furosemide * Death (all causes) * Decrease in 6 minute walk distance (6MWD) by ≥15% from baseline confirmed by 2 tests at least 4hours, but no more than 1 week apart.

Time frame:
24 Weeks
Reported as:
Median · Months
Base Study: Time to First Clinical Worsening Event (TTCW) at Weeks 24
MonthsPlacebo-Controlled Treatment Period: Sotatercept 0.3 mg/kgPlacebo-Controlled Treatment Period: Sotatercept 0.7 mg/kgPlacebo-Controlled Treatment Period: Placebo
Base Study: Time to First Clinical Worsening Event (TTCW) at Weeks 24NA (NA to NA)NA (NA to NA)NA (6.2 to NA)
Statistical analysis
  • Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg vs Placebo-Controlled Treatment Period: Placebo · Log Rank · p = 0.0023 (P-value based on log-rank test stratified by the randomization stratification factor.) · Hazard ratio (hr): 0.18 · 95% CI 0.05 to 0.62
  • Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg vs Placebo-Controlled Treatment Period: Placebo · Log Rank · p = 0.2109 (P-value based on log-rank test stratified by the randomization stratification factor.) · Hazard ratio (hr): 0.59 · 95% CI 0.25 to 1.36
SecondaryBase Study: Change From Baseline in Mean Pulmonary Arterial Pressure (mPAP) at Week 24

mPAP was calculated from systolic and diastolic pulmonary artery pressure measured by right heart catheterization. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.

Time frame:
Baseline and Week 24
Reported as:
Median · mmHg
Base Study: Change From Baseline in Mean Pulmonary Arterial Pressure (mPAP) at Week 24
mmHgPlacebo-Controlled Treatment Period: Sotatercept 0.3 mg/kgPlacebo-Controlled Treatment Period: Sotatercept 0.7 mg/kgPlacebo-Controlled Treatment Period: Placebo
Base Study: Change From Baseline in Mean Pulmonary Arterial Pressure (mPAP) at Week 24-9.1 (-10.3 to -8.0)-9.1 (-9.5 to -8.5)-0.2 (-1.0 to 0.5)
Statistical analysis
  • Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg vs Placebo-Controlled Treatment Period: Placebo · Wilcoxon (Mann-Whitney) · p = 0.001 (Two-sided p-values are provided using the aligned rank stratified Wilcoxon test stratified by the randomization stratification factor.) · Hodges-lehmann location shift: -9.19 · 95% CI -13.00 to -5.38
  • Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg vs Placebo-Controlled Treatment Period: Placebo · Wilcoxon (Mann-Whitney) · p = 0.001 (Two-sided p-values are provided using the aligned rank stratified Wilcoxon test stratified by the randomization stratification factor.) · Hodges-lehmann location shift: -9.22 · 95% CI -12.97 to -5.46
SecondaryBase Study: Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP) at Week 24

PCWP is an indirect estimate of left atrial pressure measured in right heart catheterization. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.

Time frame:
Baseline and Week 24
Reported as:
Median · mmHg
Base Study: Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP) at Week 24
mmHgPlacebo-Controlled Treatment Period: Sotatercept 0.3 mg/kgPlacebo-Controlled Treatment Period: Sotatercept 0.7 mg/kgPlacebo-Controlled Treatment Period: Placebo
Base Study: Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP) at Week 24-4.1 (-5.6 to -3.0)-3.3 (-4.0 to -3.0)-1.1 (-1.5 to -0.5)
Statistical analysis
  • Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg vs Placebo-Controlled Treatment Period: Placebo · Wilcoxon (Mann-Whitney) · p = 0.027 (Two-sided p-values are provided using the aligned rank stratified Wilcoxon test stratified by the randomization stratification factor.) · Hodges-lehmann location shift: -3.04 · 95% CI -5.77 to -0.32
  • Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg vs Placebo-Controlled Treatment Period: Placebo · Wilcoxon (Mann-Whitney) · p = 0.074 (Two-sided p-values are provided using the aligned rank stratified Wilcoxon test stratified by the randomization stratification factor.) · Hodges-lehmann location shift: -2.53 · 95% CI -5.33 to 0.28
SecondaryBase Study: Change From Baseline in Tricuspid Annular Plane Systolic Excursion (TAPSE) at Week 24

TAPSE is an echocardiographic measurement of tricuspid valve annulus movement, as an indicator of right heart function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.

Time frame:
Baseline and Week 24
Reported as:
Median · cm
Base Study: Change From Baseline in Tricuspid Annular Plane Systolic Excursion (TAPSE) at Week 24
cmPlacebo-Controlled Treatment Period: Sotatercept 0.3 mg/kgPlacebo-Controlled Treatment Period: Sotatercept 0.7 mg/kgPlacebo-Controlled Treatment Period: Placebo
Base Study: Change From Baseline in Tricuspid Annular Plane Systolic Excursion (TAPSE) at Week 24-0.2 (-0.2 to 0.0)-0.1 (-0.2 to -0.1)-0.2 (-0.2 to -0.1)
Statistical analysis
  • Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg vs Placebo-Controlled Treatment Period: Placebo · Wilcoxon (Mann-Whitney) · p = 0.388 (Two-sided p-values are provided using the aligned rank stratified Wilcoxon test stratified by the randomization stratification factor.) · Hodges-lehmann location shift: 0.09 · 95% CI -0.13 to 0.31
  • Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg vs Placebo-Controlled Treatment Period: Placebo · Wilcoxon (Mann-Whitney) · p = 0.667 (Two-sided p-values are provided using the aligned rank stratified Wilcoxon test stratified by the randomization stratification factor.) · Hodges-lehmann location shift: 0.05 · 95% CI -0.17 to 0.26
SecondaryBase Study: Change From Baseline in Right Ventricular Fractional Area Change (RVFAC) at Week 24

RVFAC is an echocardiographic measurement of percent change between right ventricular area during diastole and systole, as an indicator of right heart function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.

Time frame:
Baseline and Week 24
Reported as:
Median · Percent
Base Study: Change From Baseline in Right Ventricular Fractional Area Change (RVFAC) at Week 24
PercentPlacebo-Controlled Treatment Period: Sotatercept 0.3 mg/kgPlacebo-Controlled Treatment Period: Sotatercept 0.7 mg/kgPlacebo-Controlled Treatment Period: Placebo
Base Study: Change From Baseline in Right Ventricular Fractional Area Change (RVFAC) at Week 243.1 (2.1 to 4.8)-1.2 (-2.8 to 2.4)-0.9 (-2.1 to 1.0)
Statistical analysis
  • Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg vs Placebo-Controlled Treatment Period: Placebo · Wilcoxon (Mann-Whitney) · p = 0.086 (Two-sided p-values are provided using the aligned rank stratified Wilcoxon test stratified by the randomization stratification factor.) · Hodges-lehmann location shift: 4.14 · 95% CI -0.78 to 9.06
  • Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg vs Placebo-Controlled Treatment Period: Placebo · Wilcoxon (Mann-Whitney) · p = 0.653 (Two-sided p-values are provided using the aligned rank stratified Wilcoxon test stratified by the randomization stratification factor.) · Hodges-lehmann location shift: 1.21 · 95% CI -4.24 to 6.66
SecondaryBase Study: Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Week 24

LVEF is an echocardiographic measurement of percent change between left ventricular volume during diastole and systole, as an indicator of left heart function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.

Time frame:
Baseline and Week 24
Reported as:
Median · Percent
Base Study: Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Week 24
PercentPlacebo-Controlled Treatment Period: Sotatercept 0.3 mg/kgPlacebo-Controlled Treatment Period: Sotatercept 0.7 mg/kgPlacebo-Controlled Treatment Period: Placebo
Base Study: Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Week 24-1.0 (-2.6 to 0.5)-2.9 (-4.4 to -1.5)-0.9 (-2.2 to -0.3)
Statistical analysis
  • Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg vs Placebo-Controlled Treatment Period: Placebo · Wilcoxon (Mann-Whitney) · p = 0.841 (Two-sided p-values are provided using the aligned rank stratified Wilcoxon test stratified by the randomization stratification factor.) · Hodges-lehmann location shift: -0.40 · 95% CI -4.56 to 3.76
  • Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg vs Placebo-Controlled Treatment Period: Placebo · Wilcoxon (Mann-Whitney) · p = 0.624 (Two-sided p-values are provided using the aligned rank stratified Wilcoxon test stratified by the randomization stratification factor.) · Hodges-lehmann location shift: -0.93 · 95% CI -5.03 to 3.18
SecondaryBase Study: Change From Baseline in Isovolumic Relaxation Time (IVRT) at Week 24

IVRT is an echocardiographic measurement of the interval between closure of the aortic valve, to onset of filling by opening of the mitral valve. It was used as an indicator of diastolic dysfunction. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.

Time frame:
Baseline and Week 24
Reported as:
Median · msec
Base Study: Change From Baseline in Isovolumic Relaxation Time (IVRT) at Week 24
msecPlacebo-Controlled Treatment Period: Sotatercept 0.3 mg/kgPlacebo-Controlled Treatment Period: Sotatercept 0.7 mg/kgPlacebo-Controlled Treatment Period: Placebo
Base Study: Change From Baseline in Isovolumic Relaxation Time (IVRT) at Week 2414.8 (-2.0 to 23.0)13.1 (7.0 to 25.3)6.9 (1.0 to 11.0)
Statistical analysis
  • Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg vs Placebo-Controlled Treatment Period: Placebo · Wilcoxon (Mann-Whitney) · p = 0.819 (Two-sided p-values are provided using the aligned rank stratified Wilcoxon test stratified by the randomization stratification factor.) · Hodges-lehmann location shift: 2.32 · 95% CI -18.13 to 22.76
  • Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg vs Placebo-Controlled Treatment Period: Placebo · Wilcoxon (Mann-Whitney) · p = 0.511 (Two-sided p-values are provided using the aligned rank stratified Wilcoxon test stratified by the randomization stratification factor.) · Hodges-lehmann location shift: 5.37 · 95% CI -11.41 to 22.16
SecondaryBase Study: Change From Baseline in Ratio of Mitral Inflow Velocity E to Mitral Annular Velocity'(e') (E/e' Ratio) at Week 24

E/e' is a ratio of mitral inflow velocity E to mitral annular velocity (e') as measured by electrocardiography as an indicator of diastolic function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.

Time frame:
Baseline and Week 24
Reported as:
Median · E/e' ratio
Base Study: Change From Baseline in Ratio of Mitral Inflow Velocity E to Mitral Annular Velocity'(e') (E/e' Ratio) at Week 24
E/e' ratioPlacebo-Controlled Treatment Period: Sotatercept 0.3 mg/kgPlacebo-Controlled Treatment Period: Sotatercept 0.7 mg/kgPlacebo-Controlled Treatment Period: Placebo
Base Study: Change From Baseline in Ratio of Mitral Inflow Velocity E to Mitral Annular Velocity'(e') (E/e' Ratio) at Week 24-0.5 (-1.3 to 0.5)-1.9 (-2.5 to -0.8)-0.3 (-0.6 to 0.1)
Statistical analysis
  • Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg vs Placebo-Controlled Treatment Period: Placebo · Wilcoxon (Mann-Whitney) · p = 0.527 (Two-sided p-values are provided using the aligned rank stratified Wilcoxon test stratified by the randomization stratification factor.) · Hodges-lehmann location shift: -0.65 · 95% CI -2.92 to 1.62
  • Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg vs Placebo-Controlled Treatment Period: Placebo · Wilcoxon (Mann-Whitney) · p = 0.101 (Two-sided p-values are provided using the aligned rank stratified Wilcoxon test stratified by the randomization stratification factor.) · Hodges-lehmann location shift: -1.80 · 95% CI -4.02 to 0.43
SecondaryBase Study: Change From Baseline in the Ratio of the Peak Velocity Flow of the E Wave in Early Diastole to Peak Velocity Flow of the A Wave in Late Diastole (E/A Ratio) at Week 24

E/A is a ratio of the peak velocity flow of the E wave in the early diastole to peak velocity flow of the A wave in late diastole measured by echocardiography as an indicator of diastolic function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.

Time frame:
Baseline and Week 24
Reported as:
Median · E/A ratio
Base Study: Change From Baseline in the Ratio of the Peak Velocity Flow of the E Wave in Early Diastole to Peak Velocity Flow of the A Wave in Late Diastole (E/A Ratio) at Week 24
E/A ratioPlacebo-Controlled Treatment Period: Sotatercept 0.3 mg/kgPlacebo-Controlled Treatment Period: Sotatercept 0.7 mg/kgPlacebo-Controlled Treatment Period: Placebo
Base Study: Change From Baseline in the Ratio of the Peak Velocity Flow of the E Wave in Early Diastole to Peak Velocity Flow of the A Wave in Late Diastole (E/A Ratio) at Week 24-0.1 (-0.2 to 0.0)-0.2 (-0.3 to -0.1)0.1 (-0.1 to 0.4)
Statistical analysis
  • Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg vs Placebo-Controlled Treatment Period: Placebo · Wilcoxon (Mann-Whitney) · p = 0.106 (Two-sided p-values are provided using the aligned rank stratified Wilcoxon test stratified by the randomization stratification factor.) · Hodges-lehmann location shift: -0.26 · 95% CI -0.65 to 0.13
  • Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg vs Placebo-Controlled Treatment Period: Placebo · Wilcoxon (Mann-Whitney) · p = 0.046 (Two-sided p-values are provided using the aligned rank stratified Wilcoxon test stratified by the randomization stratification factor.) · Hodges-lehmann location shift: -0.41 · 95% CI -0.87 to 0.05
SecondaryBase Study: Change From Baseline in N-terminal Pro-hormone Brain Natriuretic Peptide (NT-proBNP) at Week 24

NT-proBNP is a circulating biomarker that reflects myocardial stretch. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.

Time frame:
Baseline and Week 24
Reported as:
Median · pg/mL
Base Study: Change From Baseline in N-terminal Pro-hormone Brain Natriuretic Peptide (NT-proBNP) at Week 24
pg/mLPlacebo-Controlled Treatment Period: Sotatercept 0.3 mg/kgPlacebo-Controlled Treatment Period: Sotatercept 0.7 mg/kgPlacebo-Controlled Treatment Period: Placebo
Base Study: Change From Baseline in N-terminal Pro-hormone Brain Natriuretic Peptide (NT-proBNP) at Week 24-100.1 (-119.5 to -86.5)-171.1 (-214.5 to -153.5)157.4 (146.0 to 164.0)
Statistical analysis
  • Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg vs Placebo-Controlled Treatment Period: Placebo · Wilcoxon (Mann-Whitney) · p = 0.004 (Two-sided p-values are provided using the aligned rank stratified Wilcoxon test stratified by the randomization stratification factor.) · Hodges-lehmann location shift: -343.72 · 95% CI -656.10 to -31.34
  • Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg vs Placebo-Controlled Treatment Period: Placebo · Wilcoxon (Mann-Whitney) · p = 0.033 (Two-sided p-values are provided using the aligned rank stratified Wilcoxon test stratified by the randomization stratification factor.) · Hodges-lehmann location shift: -402.18 · 95% CI -846.60 to 42.24
SecondaryBase Study: Change From Baseline in New York Heart Association Functional Class (NYHA FC) at Week 24

NYHA FC classified the extent of heart failure (HF). Participant HF symptoms were graded using the NYHA FC system. NYHA FC for HF ranges from Class I (no limitation of physical activity, or ordinary physical activity does not cause undue fatigue, palpitation, dyspnea \[shortness of breath\]), Class II (slight limitation of physical activity, comfortable at rest, or ordinary physical activity results in fatigue, palpitation, dyspnea \[shortness of breath\]), Class III (marked limitation of physical activity, comfortable at rest, or less than ordinary activity causes fatigue, palpitation, or dyspnea) and Class IV (unable to carry on any physical activity without discomfort, symptoms of HF at rest or if any physical activity is undertaken, discomfort increases). Participants were classified as "Improved or Maintained" or "Not Improved nor Not Maintained". Improved or Maintained = reduction in NYHA FC or no change in NYHA FC; Not Improved nor Not Maintained = increase in NYHA FC.

Time frame:
Baseline and Week 24
Reported as:
Number · Participants
Base Study: Change From Baseline in New York Heart Association Functional Class (NYHA FC) at Week 24
ParticipantsPlacebo-Controlled Treatment Period: Sotatercept 0.3 mg/kgPlacebo-Controlled Treatment Period: Sotatercept 0.7 mg/kgPlacebo-Controlled Treatment Period: Placebo
Improved NYHA FC or Maintained NYHA FC514845
Not Improved NYHA FC or Not Maintained NYHA FC3710
Statistical analysis
  • Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg vs Placebo-Controlled Treatment Period: Placebo · Cochran-Mantel-Haenszel · p = 0.050 (Based on Cochran-Mantel-Haenszel method stratified by the randomization factor.) · Odds ratio (or): 3.66 · 95% CI 0.95 to 14.15
  • Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg vs Placebo-Controlled Treatment Period: Placebo · Cochran-Mantel-Haenszel · p = 0.446 (Based on Cochran-Mantel-Haenszel method stratified by the randomization factor.) · Odds ratio (or): 1.51 · 95% CI 0.53 to 4.34
SecondaryBase Study: Change From Baseline in Myocardial Contraction Fraction (MCF) at Week 24

MCF is an echocardiographic measurement that determined the ratio of left ventricular stroke volume to myocardial volume and was an indicator of left ventricular systolic function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.

Time frame:
Baseline and Week 24
Reported as:
Median · Percent
Base Study: Change From Baseline in Myocardial Contraction Fraction (MCF) at Week 24
PercentPlacebo-Controlled Treatment Period: Sotatercept 0.3 mg/kgPlacebo-Controlled Treatment Period: Sotatercept 0.7 mg/kgPlacebo-Controlled Treatment Period: Placebo
Base Study: Change From Baseline in Myocardial Contraction Fraction (MCF) at Week 241.6 (-1.0 to 4.0)-4.1 (-5.0 to -2.5)-1.1 (-1.6 to -0.9)
Statistical analysis
  • Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg vs Placebo-Controlled Treatment Period: Placebo · Wilcoxon (Mann-Whitney) · p = 0.759 (Two-sided p-values are provided using the aligned rank stratified Wilcoxon test stratified by the randomization stratification factor.) · Hodges-lehmann location shift: 1.16 · 95% CI -6.35 to 8.67
  • Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg vs Placebo-Controlled Treatment Period: Placebo · Wilcoxon (Mann-Whitney) · p = 0.314 (Two-sided p-values are provided using the aligned rank stratified Wilcoxon test stratified by the randomization stratification factor.) · Hodges-lehmann location shift: -3.73 · 95% CI -11.23 to 3.77
SecondaryBase Study: Number of Participants With One or More Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE was reported.

Time frame:
Up to approximately 6 months
Reported as:
Count of participants · Participants
Base Study: Number of Participants With One or More Adverse Events (AEs)
ParticipantsPlacebo-Controlled Treatment Period: Sotatercept 0.3 mg/kgPlacebo-Controlled Treatment Period: Sotatercept 0.7 mg/kgPlacebo-Controlled Treatment Period: Placebo
Base Study: Number of Participants With One or More Adverse Events (AEs)495148
SecondaryBase Study: Number of Participants Who Discontinued Study Treatment Due to an AE

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE was reported.

Time frame:
Up to approximately 6 months
Reported as:
Count of participants · Participants
Base Study: Number of Participants Who Discontinued Study Treatment Due to an AE
ParticipantsPlacebo-Controlled Treatment Period: Sotatercept 0.3 mg/kgPlacebo-Controlled Treatment Period: Sotatercept 0.7 mg/kgPlacebo-Controlled Treatment Period: Placebo
Base Study: Number of Participants Who Discontinued Study Treatment Due to an AE030

Adverse events

Collected over Up to approximately 26 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kg0/54 (0%)11/54 (20.4%)45/54 (83.3%)
Placebo-Controlled Treatment Period: Sotatercept 0.7 mg/kg1/56 (1.8%)18/55 (32.7%)44/55 (80%)
Placebo-Controlled Treatment Period: Placebo2/55 (3.6%)12/55 (21.8%)37/55 (67.3%)
Extension Period: Sotatercept 0.3 mg/kg2/52 (3.8%)16/52 (30.8%)37/52 (71.2%)
Extension Period: Sotatercept 0.7 mg/kg3/47 (6.4%)16/47 (34%)37/47 (78.7%)
Extension Period: Placebo → Sotatercept 0.3 mg/kg2/22 (9.1%)12/22 (54.5%)18/22 (81.8%)
Extension Period: Placebo → Sotatercept 0.7 mg/kg1/23 (4.3%)12/23 (52.2%)21/23 (91.3%)
Most frequent serious events
Showing 10 of 134
Most frequent serious events
EventPlacebo-Controlled Treatment Period: Sotatercept 0.3 mg/kgPlacebo-Controlled Treatment Period: Sotatercept 0.7 mg/kgPlacebo-Controlled Treatment Period: PlaceboExtension Period: Sotatercept 0.3 mg/kgExtension Period: Sotatercept 0.7 mg/kgExtension Period: Placebo → Sotatercept 0.3 mg/kgExtension Period: Placebo → Sotatercept 0.7 mg/kg
Cardiac failureCardiac disorders1/543/550/551/522/473/220/23
HypertransaminasaemiaHepatobiliary disorders0/540/550/550/520/470/222/23
Acute kidney injuryRenal and urinary disorders2/541/550/551/522/470/222/23
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/542/551/550/520/470/222/23
Angina pectorisCardiac disorders0/540/550/550/520/471/221/23
Atrial fibrillationCardiac disorders0/541/551/551/520/471/221/23
Atrial flutterCardiac disorders1/540/550/550/521/471/220/23
Cardiac failure acuteCardiac disorders1/540/550/550/520/471/220/23
Pericardial effusionCardiac disorders0/540/550/550/520/471/220/23
Ventricular dysfunctionCardiac disorders0/540/550/550/520/471/220/23
Most frequent other events
Showing 10 of 69
Most frequent other events
EventPlacebo-Controlled Treatment Period: Sotatercept 0.3 mg/kgPlacebo-Controlled Treatment Period: Sotatercept 0.7 mg/kgPlacebo-Controlled Treatment Period: PlaceboExtension Period: Sotatercept 0.3 mg/kgExtension Period: Sotatercept 0.7 mg/kgExtension Period: Placebo → Sotatercept 0.3 mg/kgExtension Period: Placebo → Sotatercept 0.7 mg/kg
FallInjury, poisoning and procedural complications1/545/554/556/524/475/225/23
Upper respiratory tract infectionInfections and infestations0/543/554/555/522/471/225/23
DizzinessNervous system disorders6/547/554/555/525/473/225/23
Haemoglobin increasedInvestigations10/545/551/552/524/470/221/23
HypokalaemiaMetabolism and nutrition disorders0/543/552/551/521/474/221/23
HeadacheNervous system disorders3/547/555/554/522/474/224/23
HypotensionVascular disorders0/543/551/554/523/474/222/23
ArthralgiaMusculoskeletal and connective tissue disorders5/541/555/558/523/472/224/23
DyspnoeaRespiratory, thoracic and mediastinal disorders6/540/555/559/523/473/222/23
EpistaxisRespiratory, thoracic and mediastinal disorders7/546/554/556/528/473/221/23

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kgPlacebo-Controlled Treatment Period: Sotatercept 0.7 mg/kgPlacebo-Controlled Treatment Period: PlaceboTotal
Mean74.1 ± 7.472.0 ± 8.172.7 ± 9.272.9 ± 8.3
Sex: Female, Male
Sex: Female, Male(Participants)Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kgPlacebo-Controlled Treatment Period: Sotatercept 0.7 mg/kgPlacebo-Controlled Treatment Period: PlaceboTotal
Female354336114
Male19131951
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kgPlacebo-Controlled Treatment Period: Sotatercept 0.7 mg/kgPlacebo-Controlled Treatment Period: PlaceboTotal
Hispanic or Latino3003
Not Hispanic or Latino465253151
Unknown or Not Reported54211
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kgPlacebo-Controlled Treatment Period: Sotatercept 0.7 mg/kgPlacebo-Controlled Treatment Period: PlaceboTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American4127
White465252150
More than one race0000
Unknown or Not Reported4318
NYHA Functional Class
NYHA Functional Class(Participants)Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kgPlacebo-Controlled Treatment Period: Sotatercept 0.7 mg/kgPlacebo-Controlled Treatment Period: PlaceboTotal
Class II17192056
Class III373635108
Missing0101
PVR
PVR(dynes*sec/cm5)Placebo-Controlled Treatment Period: Sotatercept 0.3 mg/kgPlacebo-Controlled Treatment Period: Sotatercept 0.7 mg/kgPlacebo-Controlled Treatment Period: PlaceboTotal
Mean464.1 ± 207.9446.1 ± 196.7423.4 ± 169.9444.4 ± 191.6
08

Study locations

119 sites
  • PULMONARY ASSOCIATES, P.A. ( Site 1008)
    Phoenix, Arizona 85032, United States
  • University of Arizona ( Site 1006)
    Tucson, Arizona 85724-0001, United States
  • Scripps Clinic ( Site 4001)
    La Jolla, California 92037-1205, United States
  • Cedars Sinai Medical Center ( Site 1082)
    Los Angeles, California 90048, United States
  • University of California Irvine ( Site 1086)
    Orange, California 92868, United States
  • Jeffrey S.Sager MD Medical Corporation ( Site 1060)
    Santa Barbara, California 93105-5311, United States
  • Stanford University ( Site 1024)
    Stanford, California 94305, United States
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center ( Site 1028)
    Torrance, California 90502, United States
  • University Of Colorado ( Site 1013)
    Aurora, Colorado 80045, United States
  • South Denver Cardiology Associates ( Site 1091)
    Littleton, Colorado 80120, United States
  • Winchester Chest Clinic ( Site 1093)
    New Haven, Connecticut 06519-1304, United States
  • The George Washington University Medical Faculty Associates ( Site 1025)
    Washington D.C., District of Columbia 20037-3201, United States
  • Bay Area Cardiology ( Site 1071)
    Brandon, Florida 33511, United States
  • Mayo Clinic Jacksonville - PPDS ( Site 1045)
    Jacksonville, Florida 32224, United States
  • AdventHealth Orlando ( Site 1058)
    Orlando, Florida 32803, United States
  • Tampa General Hospital ( Site 1043)
    Tampa, Florida 33606, United States
  • Piedmont Atlanta Hospital ( Site 1085)
    Atlanta, Georgia 30309-1281, United States
  • Emory University ( Site 1030)
    Atlanta, Georgia 30322-1013, United States
  • Saint Alphonsus Regional Medical Center ( Site 1097)
    Boise, Idaho 83704-8880, United States
  • University of Illinois Hospital ( Site 1095)
    Chicago, Illinois 60612, United States
  • IU Health Advanced Heart and Lung Care ( Site 1092)
    Indianapolis, Indiana 46202-1218, United States
  • Ascension Medical Group St. Vincent ( Site 1076)
    Indianapolis, Indiana 46260, United States
  • University of Iowa Hospital and Clinics ( Site 1050)
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center ( Site 1020)
    Kansas City, Kansas 66160, United States
  • Norton Pulmonary Specialists ( Site 1066)
    Louisville, Kentucky 40202, United States
  • University of Louisville ( Site 1099)
    Louisville, Kentucky 40202, United States
  • University Medical Center New Orleans ( Site 1057)
    New Orleans, Louisiana 70112, United States
  • Tufts Medical Center - PPDS ( Site 1012)
    Boston, Massachusetts 02111, United States
  • Brigham and Women's Hospital [Boston, MA] ( Site 1014)
    Boston, Massachusetts 02115, United States
  • University of Michigan ( Site 1011)
    Ann Arbor, Michigan 48109, United States
  • University of Minnesota Hospitals ( Site 1062)
    Minneapolis, Minnesota 55455, United States
  • Washington University School of Medicine [Saint Louis, MO] ( Site 1022)
    St Louis, Missouri 63110, United States
  • University of Nebraska Medical Center ( Site 1053)
    Omaha, Nebraska 68198, United States
  • Pulmonary Health Physicians ( Site 1080)
    Liverpool, New York 13088, United States
  • Weill Cornell Medical College ( Site 1046)
    New York, New York 10021-9800, United States
  • University of Rochester Medical Center - PPDS ( Site 1039)
    Rochester, New York 14642, United States
  • Duke University Medical Center ( Site 1026)
    Durham, North Carolina 27710-4000, United States
  • The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital ( Site 1001)
    Cincinnati, Ohio 45219, United States
  • University Hospitals Cleveland Medical Center ( Site 1005)
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic Foundation ( Site 1065)
    Cleveland, Ohio 44195, United States
  • The Ohio State University Wexner Medical Center ( Site 1032)
    Columbus, Ohio 43210, United States
  • University of Toledo Medical Center ( Site 1070)
    Toledo, Ohio 43614, United States
  • Oregon Health Science University ( Site 1054)
    Portland, Oregon 97126, United States
  • Allegheny General Hospital ( Site 1088)
    Pittsburgh, Pennsylvania 15212-4737, United States
  • Lankenau Institute for Medical Research ( Site 1089)
    Wynnewood, Pennsylvania 19096, United States
  • Rhode Island Hospital ( Site 1033)
    Providence, Rhode Island 02903, United States
  • Medical University of South Carolina - PPDS ( Site 1003)
    Charleston, South Carolina 29425-0001, United States
  • Statcare Pulmonary Consultants - Knoxville ( Site 1031)
    Knoxville, Tennessee 37919, United States
  • Baylor University Medical Center ( Site 1096)
    Dallas, Texas 75246, United States
  • University of Texas Southwestern Medical Center ( Site 4002)
    Dallas, Texas 75390, United States
  • Intermountain Medical Center ( Site 1079)
    Murray, Utah 84107, United States
  • Inova Heart and Vascular Institute ( Site 1078)
    Falls Church, Virginia 22042, United States
  • Bon Secours St. Mary's Hospital ( Site 1069)
    Richmond, Virginia 23226, United States
  • West Virginia University ( Site 1081)
    Morgantown, West Virginia 26506, United States
  • Aurora St Luke's Medical Center ( Site 1083)
    Milwaukee, Wisconsin 53215, United States
  • Froedtert Hospital & the Medical College of Wisconsin ( Site 1051)
    Milwaukee, Wisconsin 53226, United States
  • Hôpital Erasme ( Site 1402)
    Anderlecht, Bruxelles-Capitale, Region de 1070, Belgium
  • UZ Leuven - Campus Gasthuisberg ( Site 1401)
    Leuven, Vlaams-Brabant 3000, Belgium
  • University Of Alberta ( Site 2101)
    Edmonton, Alberta T6G 2B7, Canada
  • Hamilton General Hospital-Special Immunology Services Clinic ( Site 2110)
    Hamilton, Ontario L8L 2X2, Canada
  • University Health Network ( Site 2109)
    Toronto, Ontario M5G 2N2, Canada
  • Institut Universitaire de Cardiologie et de Pneumologie ( Site 2107)
    Sainte-Foy, Quebec G1V 4G5, Canada
  • Hôpital Pasteur - CHU Nice ( Site 1311)
    Nice, Alpes-Maritimes 06000, France
  • Centre Hospitalier Universitaire du Besancon ( Site 1324)
    Besançon, Doubs 25000, France
  • Hopital de Rangueil du Toulouse ( Site 1322)
    Toulouse, Haute-Garonne 31400, France
  • CHU Montpellier Hôpital Arnaud de VIlleneuve ( Site 1301)
    Montpellier, Herault 34090, France
  • Hôpital Pontchaillou ( Site 1319)
    Rennes, Ille-et-Vilaine 35033, France
  • Centre Hospitalier Universitaire de Grenoble ( Site 1303)
    Grenoble, Isere 38043, France
  • CHU de Nantes - Hoptal Nord Laennec ( Site 1309)
    Nantes, Loire-Atlantique 44000, France
  • CHU Angers ( Site 1313)
    Angers, Maine-et-Loire 49933, France
  • CHRU de Nancy Hopitaux de Brabois ( Site 1308)
    Vandœuvre-lès-Nancy, Meurthe-et-Moselle 54500, France
  • CHRU Lille ( Site 1306)
    Lille, Nord 59037, France
  • CHU de Rouen ( Site 1323)
    Rouen, Seine-Maritime 76000, France
  • Centre Hospitalier Universitaire de Bicetre ( Site 1304)
    Le Kremlin-Bicêtre, Val-de-Marne 94270, France
  • Thoraxklinik-Heidelberg gGmbH ( Site 1509)
    Heidelberg, Baden-Wurttemberg 69126, Germany
  • Krankenhaus Neuwittelsbach ( Site 1510)
    München, Bavaria 80639, Germany
  • University Hospital Regensburg ( Site 1503)
    Regensburg, Bavaria 93053, Germany
  • Kerckhoff-Klinik-Forschungs-GmbH ( Site 1514)
    Bad Nauheim, Hesse 61231, Germany
  • Universitätsklinikum Gießen und Marburg GmbH ( Site 1512)
    Giessen, Hesse 35392, Germany
  • Medizinische Hochschule Hannover ( Site 1505)
    Hanover, Lower Saxony 30625, Germany
  • Uniklinik Köln ( Site 1511)
    Cologne, North Rhine-Westphalia 50931, Germany
  • Universitaetsmedizin Johannes Gutenberg Universitaet Mainz ( Site 1515)
    Mainz, Rhineland-Palatinate 55131, Germany
  • Universitätsklinikum Carl Gustav Carus an der TU Dresden. ( Site 1501)
    Dresden, Saxony 01307, Germany
  • DRK Kliniken Berlin Westend ( Site 1507)
    Berlin, 14050, Germany
  • Assuta Ashdod Medical Center ( Site 1710)
    Ashdod, 7747629, Israel
  • Shamir Medical Center Assaf Harofeh ( Site 1713)
    Be’er Ya‘aqov, 70300, Israel
  • Rambam Health Corp. ( Site 1716)
    Haifa, 3109601, Israel
  • Lady Davis Carmel Medical Center ( Site 1705)
    Haifa, 3436212, Israel
  • Edith Wolfson Medical Center ( Site 1717)
    Holon, 5810001, Israel
  • Shaare Zedek Medical Center ( Site 1715)
    Jerusalem, 91031, Israel
  • Hadassah Ein Kerem Medical Center ( Site 1711)
    Jerusalem, 91120, Israel
  • Meir Medical Center. ( Site 1707)
    Kfar Saba, 4428164, Israel
  • Rabin Medical Center ( Site 1703)
    Petah Tikva, 4941492, Israel
  • Kaplan Medical Center ( Site 1712)
    Rehovot, 7610001, Israel
  • ZIV Medical Center ( Site 1704)
    Safed, 13100, Israel
  • Tel Aviv Sourasky Medical Center ( Site 1714)
    Tel Aviv, 64239, Israel
  • AOU di Bologna Policlinico S Orsola Malpighi ( Site 2409)
    Bologna, Emilia-Romagna 40138, Italy
  • Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI) ( Site 2405)
    Trieste, Friuli Venezia Giulia 34149, Italy
  • Fondazione IRCCS San Gerardo dei Tintori - ASST di Monza - A. O. San Gerardo ( Site 2406)
    Monza, Lombardy 20900, Italy
  • Fondazione IRCCS-Policlinico San Matteo ( Site 2401)
    Pavia, Lombardy 27100, Italy

Showing the first 100 of 119 sites across 12 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Gomberg-Maitland M, Tedford RJ, Langleben D, Rosenkranz S, Miller B, Jones AD, Urbinati A, McMullan CJ, Cornell AG, Vachiery JL. Sotatercept for Combined Post- and Precapillary Pulmonary Hypertension Associated With Heart Failure: Results From the Phase 2, Randomized, Placebo-Controlled CADENCE Study. Circulation. 2026 May 12;153(19):1446-1459. doi: 10.1161/CIRCULATIONAHA.126.079918. Epub 2026 Mar 29. PubMed 41904795 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Sep 2025, 44 months.

Results were first posted in Sep 2026, 1 year after primary completion.

Of 50 phase 2 interventional studies under Hypertension, Pulmonary, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 71. This study's 44 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2021
First posted
Jun 30, 2021
StartActual
Dec 29, 2021
Primary completionActual
Sep 5, 2025
CompletionActual
Apr 9, 2026
Results first posted
Sep 23, 2026
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04945460
Responsible party
Sponsor
First posted
Jun 30, 2021
Start date
Dec 29, 2021
Primary completion
Sep 5, 2025
Completion
Apr 9, 2026
Results posted
Sep 23, 2026
Last update
Sep 23, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotatercept

Start the discussion